Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma, Malignant × dostarlimab × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 9 Neoplasms 4 Lung Neoplasms 3 Neoplasm Metastasis 2 Melanoma 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) 1 Mesothelioma, Malignant 1 Mesothelioma 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Neuroendocrine 1 Breast Neoplasms 1

Interventions

Cisplatin 54 Pemetrexed 43 pembrolizumab 16 Nivolumab 14 Carboplatin 14 Gemcitabine 13 Cyclophosphamide 10 Radiotherapy 9 Drug Therapy 8 atezolizumab 7 Ipilimumab 7 durvalumab 6 Platinum 6 Doxorubicin 6 1,2-diaminocyclohexaneplatinum II citrate 6 tremelimumab 5 sodium thiosulfate 5 Vinorelbine 5 Radiotherapy, Intensity-Modulated 5 Chemotherapy, Adjuvant 5 Cerebral Decortication 5 sargramostim 4 defactinib 4 tumor necrosis factor-alpha, CNGRC fusion protein, human 3 Photochemotherapy 3 Neoadjuvant Therapy 3 Mitomycin 3 Interleukin-2 3 Dihematoporphyrin Ether 3 Decitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03654833 2023-03-14

MiST

University of Leicester

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡